Inflammation Research

, Volume 44, Issue 1, pp 1–10

New insights into the mode of action of anti-inflammatory drugs

  • J. R. Vane
  • R. M. Botting


The discovery of a second cyclooxygenase has provided fresh impetus to the search for new anti-inflammatory drugs. The second enzyme is effectively absent from healthy tissues but its levels rise dramatically during inflammation. It can be induced in migratory cells by bacterial lipopolysaccharide, cytokines and growth factors. The constitutive cyclooxygenase-1 (COX-1) can thus be considered a “housekeeping” enzyme, in contrast to cyclooxygenase-2 (COX-2) which is activated by tissue damage. Both enzymes have a molecular weight of around 70kDa and similar Km and Vmax values for their reaction with arachidonic acid. Several non steroid anti-inflammatory drugs which have more than 1,000 fold selectivity for COX-2 over COX-1 are in the early stages of drug development.

Key words

Cyclooxygenase-1 Cyclooxygenase-2 Prostaglandins Non-steroid anti-inflammatory drugs Anti-inflammatory steroids 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Weissmann G, Thomas L. Studies on lysosomes. II. The effect of cortisone on the release of acid hydrolases from a large granule fraction of rabbit liver induced by an excess of Vitamin A. J Clin Invest 1963;42:661–9.Google Scholar
  2. [2]
    Whitehouse MW, Haslam JM. Ability of some antirheumatic drugs to uncouple oxidative phosphorylation. Nature 1962;196:1323–4.Google Scholar
  3. [3]
    Hines WJW, Smith MJH. Inhibition of dehydrogenases by salicylate. Nature 1964;201:192.Google Scholar
  4. [4]
    Smith MJH, Bryant C, Hines WJW. Reversal by nicotinamide adenine dinucleotide of the inhibitory action of salicylate on mitochondrial malate dehydrogenase. Nature 1964;202:96–7.Google Scholar
  5. [5]
    Gould BJ, Smith MJH. Salicylate and aminotransferases. J Pharm Pharmacol 1965;17:83–8.Google Scholar
  6. [6]
    Gould BJ, Smith MJH. Inhibition of rat brain glutamate decarboxylase activity by salicylate in vitro. J Pharm Pharmacol 1965;17:15–8.Google Scholar
  7. [7]
    Weiss WP, Campbell PL, Diebler GE, Sokoloff L. Effects of salicylate on amino acid incorporation into protein. J Pharmacol Exp Ther 1962;136:366–71.Google Scholar
  8. [8]
    Collier HOJ. Aspirin. Sci Am 1963;209:97–108.Google Scholar
  9. [9]
    Collier HOJ. A pharmacological analysis of aspirin. Adv Pharmacol Chemother 1969;7:333–405.Google Scholar
  10. [10]
    Vane JR. The use of isolated organs for detecting active substances in the circulating blood. Br J Pharmacol Chemother 1964;23:360–73.Google Scholar
  11. [11]
    Piper PJ, Vane JR. Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 1969;223:29–35.Google Scholar
  12. [12]
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biology) 1971;231:232–5.Google Scholar
  13. [13]
    Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971;231:235–37.Google Scholar
  14. [14]
    Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from spleen. Nature 1971;231:237–239.Google Scholar
  15. [15]
    Flower RJ, Vane JR. Inhibition of prostaglandin biosynthesis. Biochem Pharmac 1974;23:1439–50.Google Scholar
  16. [16]
    Higgs GA, Moncada S, Vane JR. Eicosanoids in inflammation. Ann Clin Res 1984;16:287–99.Google Scholar
  17. [17]
    Vane JR, Botting RM. The mode of action of anti-inflammatory drugs. Postgrad Med J 1990;66 (Suppl 4):S2-S17.Google Scholar
  18. [18]
    Murphy RC, Hammarström S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979;76:4275–9.Google Scholar
  19. [19]
    Hemler M, Lands WEM, Smith WL. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of the two forms of iron in the holoenzyme. J Biol Chem 1976;251:5575–9.Google Scholar
  20. [20]
    Miyamoto T, Ogino N, Yamamoto S, Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976;251:2629–36.Google Scholar
  21. [21]
    Kulmacz RJ, Pendleton RB, Lands WEM. Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics. J Biol Chem 1994;269:5527–36.Google Scholar
  22. [22]
    Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandinH 2 synthase-1. Nature 1994;243–9.Google Scholar
  23. [23]
    Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975;72:3073–6.Google Scholar
  24. [24]
    Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandinH 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737–40.Google Scholar
  25. [25]
    Masferrer JL, Zweifel BS, Seibert S, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375–9.Google Scholar
  26. [26]
    Xie W, Chipman JG, Robertson DL, Erikson RL. Simmons DL, Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692–6.Google Scholar
  27. [27]
    O'Banion MK, Sadowski HB, Winn V, Young DA. A serumand glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261–7.Google Scholar
  28. [28]
    Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS 10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992;267:7991–4.Google Scholar
  29. [29]
    Sirois J, Richards JS. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267:6382–8.Google Scholar
  30. [30]
    Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992;263:F181-F191.Google Scholar
  31. [31]
    Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1992;268:6610–4.Google Scholar
  32. [32]
    DeWitt DL. Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim Biophys Acta 1991;1083:121–34.Google Scholar
  33. [33]
    Wu KK, Sanduja R, Tsai A-L, Ferhanoglu B, Loose-Mitchell DS. Aspirin inhibits interleukin-1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci USA 1991;88:2384–7.Google Scholar
  34. [34]
    Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet-erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB J. 1991;5:2304–12.Google Scholar
  35. [35]
    O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993;330:156–160.Google Scholar
  36. [36]
    Whittle BJR. Relationship between the prevention of rat gastric erosions and the inhibition of acid secretion by prostaglandins. Eur J Pharmacol 1976;40:233–9.Google Scholar
  37. [37]
    Carmichael HA, Nelson LM, Russell RJ. Cimetidine and prostaglandin: evidence for different modes of action on the rat gastric mucosa. Gastroenterology 1978;74:1229–32.Google Scholar
  38. [38]
    Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983;245:G601-G623.Google Scholar
  39. [39]
    Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats—prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl and thermal injury. Gastroenterology 1979;77:433–43.Google Scholar
  40. [40]
    Dunn MJ, Zambraski EJ. Renal effects of drugs that inhibit prostaglandin synthesis. Kidney Int 1980;18:609–22.Google Scholar
  41. [41]
    Zambraski EJ, Dunn MJ. Renal effects of aspirin. In J. R. Vane, R. M. Botting, eds. Aspirin and Other Salicylates. London: Chapman and Hall 1992;510–31.Google Scholar
  42. [42]
    Keirse M. In Keirse M, Anderson A, Bennebroek Gravenhorst, eds. Human Parturition. The Hague: Martinus Nijhoff, 1979:101–142.Google Scholar
  43. [43]
    Mitchell MD. Prostaglandins during pregnancy and the perinatal period. J Reprod Fertil 1981;62:305–515.Google Scholar
  44. [44]
    Okazaki T, Casey ML, Okita JR, MacDonald PC, Johnston JM. Initiation of human parturition. XII. Biosynthesis and metabolism of prostaglandins in human fetal membranes and uterine decidua. Am J Obstet Gynecol 1981;139:373–81.Google Scholar
  45. [45]
    Mitchell MD. The mechanism(s) of human parturition. J Dev Physiol 1984;6:107–18.Google Scholar
  46. [46]
    Bennett P, Slater D, Berger L, Moore G. The expression of phospholipaseA 2 and lipocortins (annexins) I, II and V in human fetal membranes and placenta in association with labour. Prostaglandins 1994;48:81–90.Google Scholar
  47. [47]
    Heyman MA, Rudolph AM, Silverman WH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976;295:530–533.Google Scholar
  48. [48]
    Stefanczyk-Krzymowska S, Szafranska B, Kaminski T, Krzymowski T. Total content of prostaglandinF in the endometrium and myometrium from various sections of the porcine uterine horn during the estrous cycle. Prostaglandins 1994;48:99–108.Google Scholar
  49. [49]
    Gadsby JE, Earnest KL. ProstaglandinF stimulates progesterone secretion by porcine luteal cells in vitro throughout the estrous cycle. Prostaglandins 1994;48:109–25.Google Scholar
  50. [50]
    Benedetto C. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol 1989;3:71–94.Google Scholar
  51. [51]
    Solomon LM, Juhlin L, Kirchenbaum MB. Prostaglandins on cutaneous vasculature. J Invest Derm 1968;51:280–2.Google Scholar
  52. [52]
    Williams TJ, Peck MJ. Role of prostaglandin-mediated vasodilation in inflammation. Nature 1977;270:530–2.Google Scholar
  53. [53]
    Ferreira SH. Prostaglandins, aspirin-like drugs and analgesia. Nature 1972;240:200–3.Google Scholar
  54. [54]
    Saxena PN, Beg MMA, Singhal KC, Ahmad M. Prostaglandin-like activity in the cerebrospinal fluid of febrile patients. Indian J Med Res 1979;79:495–8.Google Scholar
  55. [55]
    Higgs EA, Moncada S, Vane JR. Inflammatory effects of prostacyclin (PGI 2) and 6-oxo-PGF in the rat paw. Prostaglandins 1978;16:153–62.Google Scholar
  56. [56]
    Chepenik KP, Diaz A, Jimenez SA. Epidermal growth factor coordinately regulates the expression of prostaglandin G/H synthase and cytosolic phospholipaseA 2 genes in embryonic mouse cells. J Biol Chem 1994;269:21786–92.Google Scholar
  57. [57]
    Wallner BP, Mattaliano RJ, Hession C, Cate RL, Tizard R, Sinclair LK, Foeller C, Chow EP, Browning JL, Ramachandran KL, Pepinsky RB. Cloning and expression of human lipocortin, a phospholipaseA 2 inhibitor with potent anti-inflammatory activity. Nature 1986;320:77–81.Google Scholar
  58. [58]
    Flower RJ, Rothwell NJ. Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol Sci 1994;15:71–6.Google Scholar
  59. [59]
    Geisow MJ, Walker JH, Boustead C, Taylor W. Localisation and structures of novel calcium-regulated phospholipid-binding proteins. Biochem Soc Trans 1987;15:800–2.Google Scholar
  60. [60]
    Cirino G, Flower RJ. Human recombinant lipocortin 1 inhibits prostacyclin production by human umbilical artery in vitro. Prostaglandins 1987;34:59–62.Google Scholar
  61. [61]
    Cirino G, Peers SH, Flower RJ, Browning JL, Pepinsky RB. Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test. Proc Natl Acad Sci USA 1989;86:3428–32.Google Scholar
  62. [62]
    Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993;14:436–41.Google Scholar
  63. [63]
    Higgs GA, Vane JR, Hart FD, Wojtulewski JA. Effects of anti-inflammatory drugs on prostaglandins in rheumatoid arthritis. In: H. J. Robinson, J. R. Vane, eds. Prostaglandin synthetase inhibitors. New York: Raven Press, 1974;165–73.Google Scholar
  64. [64]
    Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974;26:33–67.Google Scholar
  65. [65]
    Shen TY. Prostaglandin synthetase inhibitors. In Vane JR, Ferreira SH, eds. Antiinflammatory Drugs. Berlin, Springer-Verlag 1979:305–347.Google Scholar
  66. [66]
    Preston SJ, Arnold MH, Beller EM, Brooks PM, Buchanan WW. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicyclic acid (aspirin) in rheumatoid arthritis. Br J Clin Pharmacol 1989;27:607–11.Google Scholar
  67. [67]
    Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclo-oxygenase and anti-inflammatory activity. Proc Natl Acad Sci USA 1987;84:1417–20.Google Scholar
  68. [68]
    Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271–3.Google Scholar
  69. [69]
    Vargaftig BB. Salicylic acid fails to inhibit generation of thromboxaneA 2 activity in platelets after in vivo administration to the rat. J Pharm Pharmacol 1978;30:101–4.Google Scholar
  70. [70]
    Sanduja R, Loose-Mitchell D, Wu KK. Inhibition of de novo synthesis and message expression of prostaglandin H synthase by salicylates. Adv Prostaglandin Thromboxane Leukotriene Res 1991;21:149–52.Google Scholar
  71. [71]
    Kopp E, Ghosh S. Inhibition of NF-kB by sodium salicylate and aspirin. Science 1994;265:956–9.Google Scholar
  72. [72]
    Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240:410–11.Google Scholar
  73. [73]
    Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693–7.Google Scholar
  74. [74]
    Engelhardt G. Meloxicam: lack of correlation between inhibition of PG biosynthesis in the inflammatory field and in the stomach. Magy Rheumatol 1991;32 (Suppl.):354, Abstr. P4-277.Google Scholar
  75. [75]
    Engelhardt G. Meloxicam. A potent inhibitor of COX-2. Abstracts of 9th International Conference on Prostaglandins and Related Compounds. Florence (Italy), 6–10 June, 1994, p 82.Google Scholar
  76. [76]
    Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81–106.Google Scholar
  77. [77]
    Appleton I, Tomlinson A, Chander CL, Willoughby DL. Effect of endothelin-1 on croton oil-induced granulation tissue in the rat. Lab Invest 1992;67:703–10.Google Scholar
  78. [78]
    Appleton I, Tomlinson A, Colville-Nash P, Willoughby DA, Temporal and spatial immunolocalization of cytokines in murine chronic granulomatous tissue. Implications for their role in tissue development and repair processes. Lab Invest 1993;69:405–14.Google Scholar
  79. [79]
    Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046–50.Google Scholar
  80. [80]
    Willoughby DA. Human arthritis applied to animal models: towards a better therapy. Herberden Oration 1974. Ann Rheum Dis 1975;34:471–8.Google Scholar
  81. [81]
    Gorbunov N, Esposito E. Nitric oxide as a mediator of inflammation. International Journal of Immunopathology and Pharmacology 1993;6:67–75.Google Scholar
  82. [82]
    Bailey JM, Verma M. Analytical procedures for a cryptic messenger RNA that mediates translational control of prostaglandin synthase by glucocorticoids. Anal Biochem 1991;196:11–18.Google Scholar
  83. [83]
    Schini BB, Durante W, Elizondo E, Scott-Burden T, Jubquero DC, Schafer AL, Vanhoutte PM. The induction of nitric oxide synthase activity is inhibited by TGF-β1,PDGF AB andPDGF BB in vascular smooth muscle cells. Eur J Pharmacol 1992;216:379–83.Google Scholar
  84. [84]
    Swierkosz TA, Mitchell JA, Tomlinson A, Warner TD, Thiemermann C, Vane JR. Co-release and interactions of nitric oxide and prostanoids in vitro and in vivo following exposure to bacterial lipopolysaccharide. In: Biology of Nitric Oxide. (ed. Moncada S, Feelisch M, Higgs EA) Portland Press, London. (in press).Google Scholar
  85. [85]
    Stadler J, Stefanovic-Racic M, Billiar TR, Curran RD, McIntyre LA, Georgescu HI, Simmons RL, Evans CH. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 1991;147:3915–20.Google Scholar
  86. [86]
    Stadler J, Harbrecht BG, Di Silvio M, Curran RD, Jordan RD, Simmons RL, Billiar TR. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukocyte Biol 1993;53:165–72.Google Scholar
  87. [87]
    Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228–32.Google Scholar
  88. [88]
    Needleman P. In search of a better NSAID. 9th International Conference on Prostaglandins and Related Compounds. Florence (Italy) June 6–10, 1994.Google Scholar
  89. [89]
    Chan C-C, Gordon R, Brideau C, Rodger IW, Li CS, Prasit P, Tagari P, Ethier D, Vickers P, Boyce S, Rupniak N, Webb J, Hill R, Ford-Hutchinson AW. In vivo pharmacology of L-745,337: a novel non-steroidal antiinflammatory agent (NSAID) with an ulcerogenic sparing effect in rat and monkey stomach. Can J Physiol Pharmacol 1994;72(Suppl 1):266.Google Scholar
  90. [90]
    Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, Ackerman NR. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990;254:180–7.Google Scholar
  91. [91]
    Hirschelmann R, Hentschel M, Geissler J, Rickinger O. CGP 28238, a new potent nonsteroidal antiinflammatory agent: Its relation to arachidonic acid metabolism. Agents Actions 1991;32:54–5.Google Scholar
  92. [92]
    Klein T, Nüsing RM, Ullrich V. Selective inhibition of cyclooxygenase 2. Abstracts of the 9th International Conference on Prostaglandins and Related Compounds. Florence (Italy) June 6–10, 1994. p 82.Google Scholar
  93. [93]
    Wiesenberg-Boettcher I, Schweizer A, Green JR, Mueller K, Maerki F, Pfeilschifter J. The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound. Drugs Exp Clin Res 1989;15:501–9.Google Scholar
  94. [94]
    Tagari P, Panneton M, Rasori R. Assessment of NSAID gastroenteropathy in primates. Can J Physiol Pharmacol 1994;72(Suppl 1):267.Google Scholar
  95. [95]
    Parnham MJ. Inflammation '93. Drug News Perspect 1994;6:737–42 (1994).Google Scholar
  96. [96]
    Futaki N, Takahashi S, Yokoyama M, Arai S, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55–9.Google Scholar
  97. [97]
    Futaki N, Arai I, Hamasaka Y, Takahashi S, Higuchi S, Otomo S. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol 1993;45:753–5.Google Scholar
  98. [98]
    Bendele AM, Benslay DN, Hom JT, Spaethe SM, Rutebories KJ, Lindstrom TD, Lee SJ, Naismith RW. Anti-inflammatory activity of BF389, a Di-T-butylphenol, in animal models of arthritis. J Pharmacol Exp Ther 1992;260:300–5.Google Scholar
  99. [99]
    Wong S, Lee SJ, Frierson MR, Proch J, Miskowski TA, Rigby BS, Schmolka SJ, Naismith RW, Kreutzer DC, Lindquist R. Antiarthritic profile of BF-389—a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions 1992;37:90–8.Google Scholar
  100. [100]
    Battistini B, Botting R, Bakhle YS. COX-1 and COX-2: Toward the development of more selective non-steroid anti-inflammatory drugs. Drugs News and Perspectives 1994. In press.Google Scholar

Copyright information

© Birkhäuser Verlag 1995

Authors and Affiliations

  • J. R. Vane
    • 1
  • R. M. Botting
    • 1
  1. 1.The William Harvey Research InstituteSt Bartholomew's Hospital Medical CollegeLondonUK

Personalised recommendations